ROSE12, a novel anti-CTLA-4 Fc{gamma}Rs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation Background <p>Intratumoral regulatory T cells (Tregs) are associated with diminished antitumor immunity and poor prognosis in many cancers, with tumor-infiltrating effector Tregs expressing high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). While Treg depletion is a promising strategy for cancer immunotherapy, systemic Treg depletion may lead to severe autoimmune toxicity. Therefore, to selectively deplete intratumoral Tregs, we used extracellular ATP… Journal for ImmunoTherapy of Cancer January 9, 2026 Original source
Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms <p>Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors, including tumor heterogeneity, immune exclusion, and a profoundly immunosuppressive tumor microenvironment. This review provides a comprehensive analysis of current ACT modalities, including tumor-infiltrating lymphocytes, T cell receptor-engineered, and chimeric antigen receptor-T cell… Journal for ImmunoTherapy of Cancer January 9, 2026 Original source
Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations Background <p>Engineering chimeric antigen receptor (CAR) T cells with logic-gated synthetic Notch (synNotch) receptor circuits can enhance specificity and mitigate on-target/off-tumor toxicity. However, the conventional synNotch system uses two lentiviral vectors encoding the synNotch receptor and inducible CAR, requiring dual transduction and cell sorting, which limits clinical translation. Integrating the synNotch-CAR circuit into a single lentiviral vector could overcome this… Journal for ImmunoTherapy of Cancer January 9, 2026 Original source
CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation Background <p>Oncolytic herpes simplex virus (oHSV) therapy is a live virus-based immunotherapy that lyses tumor cells which release antigens and activate antitumor immunity. oHSV therapy has been shown to increase ATP production and release of extracellular ATP (eATP). In the extracellular tumor microenvironment, eATP functions as an immune-activating damage-associated molecular pattern but is hydrolyzed to extracellular adenosine (eADO), which can… Journal for ImmunoTherapy of Cancer January 8, 2026 Original source
Systematic evaluation of neoepitope predictions challenges clinically observed T-cell responses and their impact on immune evasion Abstract <p>Peptide presentation on human leukocyte antigens (HLAs) is essential for initiating T-cell responses and all consequences of this presentation including anticancer immunity or immune escape. Many studies have relied on in silico prediction tools rather than biological measurement of HLA presentation to study these effects. To better assess the frequency and consequences of neoantigen presentation, we overexpressed 125 combinations… Journal for ImmunoTherapy of Cancer January 8, 2026 Original source
Opportunity knocking: shared tumor-associated antigen vaccines against global cancer pandemic <p>Shared tumor-associated antigen (TAA) vaccines are the legacy of several generations of cancer immunologists who have labored to bring them to patients with cancer to improve their disease outcome and eventually use them to prevent cancer. TAA vaccines failed as monotherapy but the development of checkpoint inhibitors and other reagents that can modify immunosuppressive tumor microenvironment, warrants their reassessment in… Journal for ImmunoTherapy of Cancer January 8, 2026 Original source
Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers Background <p>Mismatch repair deficiency (dMMR) colorectal cancer (CRC) is characterized by abundant tumor-infiltrating lymphocytes and tertiary lymphoid structures (TLSs). However, while B cells are pivotal for TLS formation, their function and the signaling pathways driving their activation in dMMR CRCs remain undefined.</p> Methods <p>Data from The Cancer Genome Atlas (TCGA) database analyzed by XCELL method and multiplex immunofluorescence (MIF) staining… Journal for ImmunoTherapy of Cancer January 8, 2026 Original source
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study <p>Prostate Cancer and Prostatic Diseases, Published online: 08 January 2026; <a href="https://www.nature.com/articles/s41391-025-01067-3">doi:10.1038/s41391-025-01067-3</a></p>Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study Prostate Cancer Journal January 8, 2026 Original source
Erratum to ‘Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis’ The publisher regrets a spelling error in the published article. Annals of Oncology January 8, 2026 Original source
Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort <p>Prostate Cancer and Prostatic Diseases, Published online: 07 January 2026; <a href="https://www.nature.com/articles/s41391-025-01070-8">doi:10.1038/s41391-025-01070-8</a></p>Validation of the Prostatype® P-score for predicting prostate cancer specific mortality in a multiethnic U.S. veterans cohort Prostate Cancer Journal January 7, 2026 Original source
Donating Her Blood Stem Cells to Patient is a No-Brainer for Dana-Farber Staffer <p>The call from the National Marrow Donor Program (NMDP) seemed to come from out of nowhere, but it bore some hopeful news: Dana-Farber senior project manager Alexandria Monteiro’s stem cells were a match for a stranger with leukemia who needed a stem cell transplant. “I don’t remember signing up,” Monteiro admits, “but based on who I know myself to be,”… Dana-Farber Cancer Institute January 7, 2026 Original source
Tumor-infiltrating microbes and therapy response: a new frontier in triple-negative breast cancer precision oncology <p>Tumor-infiltrating microbes are emerging as a novel dimension of cancer biology, with growing evidence suggesting their potential as prognostic and predictive biomarkers. In this issue, Chen <i>et al</i> demonstrate associations between microbial signatures and treatment response in triple-negative breast cancer (TNBC). They join a growing list of examples whereby tumor-infiltrating microbes influence therapeutic efficacy, with mechanisms ranging from drug metabolism… Journal for ImmunoTherapy of Cancer January 7, 2026 Original source
What You Need to Know About Fiber and Cancer Risk <p>Feeling constipated? You may have not be getting enough fiber in your diet.   Fiber-rich diets are a key component to preventing and reducing constipation and can help you maintain a healthy gut. Dietary fiber offers many health benefits from reducing chronic diseases like diabetes to lowering your risk of some types of cancer, such as colorectal cancer.  Fiber is an undigested nutrient that passes through the body when you consume fruits, ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/01/fiber-and-cancer-risk/" title="What… Dana-Farber Cancer Institute January 7, 2026 Original source
Intratumoral dendritic cell immunotherapy controls dissemination of metastasis-initiating cancer cells, even in patients with metastatic breast cancer <p>Patients with metastatic breast cancer (MBC) have limited opportunities for a cure, as they develop resistance to therapies and continually form new metastases. Clinical overt metastases emerge from metastasis-initiating cancer cells (MICs) that disseminate during breast cancer (BC) progression. Currently, there are no available therapies that inhibit MIC dissemination to prevent overt metastasis. We provide preclinical evidence that intratumoral (IT)… Journal for ImmunoTherapy of Cancer January 6, 2026 Original source
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy Background <p>The immunonutritional background has been deeply implicated in cancer behavior and clinical outcomes. In this study, we explored the prognostic impact of the Controlling Nutritional Status (CONUT) score through its correlation with blood immunophenotypes and cytokines to provide an easily available non-invasive tool to predict the survival benefit from first-line immune checkpoint inhibitors±chemotherapy (ICI±CHT) in patients affected by advanced… Journal for ImmunoTherapy of Cancer January 6, 2026 Original source
Cannabidiol suppresses emergency MDSCs generation by disturbing EEF1B2-mediated C/EBP{beta} protein synthesis in colorectal adenomas Background <p>Colorectal cancer often develops from adenomas over years, necessitating early intervention. Myeloid-derived suppressor cells (MDSCs) are major immune suppressive cell types in colon cancer development from adenomas through early inflammation-induced emergency myelopoiesis. Cannabidiol (CBD) is reported to function in psychosis, coronavirus infection and some cancers through immune regulation. However, its target and underlying mechanisms in colorectal adenomas are unknown.</p>… Journal for ImmunoTherapy of Cancer January 5, 2026 Original source
Opportunities and challenges of targeting cGAS–STING in cancer <p>Nature Reviews Cancer, Published online: 05 January 2026; <a href="https://www.nature.com/articles/s41568-025-00894-9">doi:10.1038/s41568-025-00894-9</a></p>In this Review, Lu et al. discuss the dual role of the cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)–stimulator of interferon genes (STING) pathway in cancer, emphasizing its involvement in both tumour suppression and promotion. They highlight the diverse sources of pathway activation and suggest that this functional duality may underlie the… Nature Reviews Cancer January 5, 2026 Original source
Testicular Cancer Survivor is On the Run and Spreading the Word <p>Devon Choi had a great job, a terrific group of friends, and had just run the Boston Marathon – the first of six 26.2-mile races he hoped to complete in major cities around the world.   So, when the East Boston resident felt a lump on his left testicle while showering in May 2023, he shrugged it off. Choi was ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/01/testicular-cancer-survivor-running-to-spread-awareness/" title="Testicular… Dana-Farber Cancer Institute January 5, 2026 Original source
Convergence of machine learning and genomics for precision oncology <p>Nature Reviews Cancer, Published online: 02 January 2026; <a href="https://www.nature.com/articles/s41568-025-00897-6">doi:10.1038/s41568-025-00897-6</a></p>In this Perspective, Reardon et al. explore how integrating machine learning into next-generation sequencing (NGS)-based molecular diagnostic workflows can enhance precision oncology. They discuss the benefits, challenges and responsible implementation of these approaches, highlighting their potential to streamline variant interpretation, maximize clinical insights and support more informed decision-making at the point-of-care. Nature Reviews Cancer January 2, 2026 Original source
Double trouble for the tumour glycocode <p>Nature Reviews Cancer, Published online: 02 January 2026; <a href="https://www.nature.com/articles/s41568-025-00902-y">doi:10.1038/s41568-025-00902-y</a></p>By incorporating lectins that target specific tumour-associated carbohydrate antigens, Zhou et al. engineered bispecific antibodies that induce effective T cell activation and tumour regression in various cancers. Nature Reviews Cancer January 2, 2026 Original source